Feedback
Settings

Settings

Goto Application

1. WO2021255218 - A PHARMACEUTICAL COMBINATION COMPRISING AN ANTI-VIRAL PROTONOPHORE AND A SERINE PROTEASE INHIBITOR

Submit observation
PermaLink
Publication Number WO/2021/255218
Publication Date 23.12.2021
International Application No. PCT/EP2021/066543
International Filing Date 18.06.2021
IPC
A61K 31/609 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
60Salicylic acid; Derivatives thereof
609Amides, e.g. salicylamide
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
A61K 31/24 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
235having an aromatic ring attached to a carboxyl group
24having an amino or nitro group
A61K 31/245 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
235having an aromatic ring attached to a carboxyl group
24having an amino or nitro group
245Amino benzoic acid types, e.g. procaine, novocaine
CPC
A61K 31/245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
235having an aromatic ring attached to a carboxyl group
24having an amino or nitro group
245Amino benzoic acid types, e.g. procaine, novocaine
A61K 31/609
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
60Salicylic acid; Derivatives thereof
609Amides, e.g. salicylamide
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Applicants
  • CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN [DE]/[DE]
Inventors
  • WITZENRATH, Martin
  • MÜLLER, Marcel Alexander
  • DROSTEN, Christian
  • CORMAN, Max
Agents
  • HERTIN UND PARTNER RECHTS- UND PATENTANWÄLTE
Priority Data
10 2020 116 249.919.06.2020DE
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) A PHARMACEUTICAL COMBINATION COMPRISING AN ANTI-VIRAL PROTONOPHORE AND A SERINE PROTEASE INHIBITOR
(FR) COMBINAISON PHARMACEUTIQUE COMPRENANT UN PROTONOPHORE ANTIVIRAL ET UN INHIBITEUR DE SÉRINE PROTÉASE
Abstract
(EN) The invention relates to a pharmaceutical combination, comprising a therapeutically effective amount of an anti-viral protonophore, and a therapeutically effective amount of a serine protease inhibitor. In preferred embodiments the invention relates to a combination of niclosamide and camostat mesylate. The invention further relates to a pharmaceutical composition comprising the combination, and use of the combination or composition in a treatment and/or prevention of a viral infection in a subject and/or a medical condition associated with a viral infection. In preferred embodiments the invention relates to the treatment and/or prevention of a SARS-CoV virus, preferably SARS-CoV-2.
(FR) L'invention concerne une combinaison pharmaceutique comprenant une quantité thérapeutiquement efficace d'un protonophore antiviral, et une quantité thérapeutiquement efficace d'un inhibiteur de sérine protéase. Dans des modes de réalisation préférés, l'invention concerne une combinaison de niclosamide et de mésylate de camostat. L'invention concerne en outre une composition pharmaceutique comprenant la combinaison, et l'utilisation de la combinaison ou de la composition dans un traitement et/ou la prévention d'une infection virale chez un sujet et/ou d'un état médical associé à une infection virale. Dans des modes de réalisation préférés, l'invention concerne le traitement et/ou la prévention d'un virus SARS-CoV, de préférence le SARS-CoV-2.
Latest bibliographic data on file with the International Bureau
# -